+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a new strategy to improve the rapid and accurate identification of febrile children aged 2 to under 5 years at risk of life-threatening infections in sub-Saharan Africa. The study compares the current standard of care using IMCI-based guidelines to a new method that adds a rapid point-of-care test measuring suPAR biomarker levels. The goal is to see if this combined approach leads to better decisions about hospital admission, referral, or discharge, and ultimately improves health outcomes. The trial involves two groups one receiving standard IMCI-based care and the other receiving IMCI-based care enhanced by suPAR testing. Blood samples will be taken from all children, but only those in the suPAR group will have their suPAR levels measured on-site using a special device. Decisions about admitting or discharging children during the first clinical assessment will be guided by these results, especially for those with higher suPAR levels indicating greater risk. A second clinical assessment by an independent physician will help ensure safety and confirm decisions. Participants will be monitored with follow-up visits on days 3 and 7 after enrollment, plus additional check-ins if their condition worsens. A 28-day follow-up interview will track serious events, hospitalizations, or deaths, with an optional 3-month follow-up for further health status updates. Throughout the study, children will receive routine treatments as needed. Researchers will measure the appropriateness of discharge decisions, hospital referrals, survival, symptom duration, and other health outcomes to assess the new triage method.

Age: 2Months - 60MonthsAll GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Healthy Volunteer

Multidrug-resistant tuberculosis MDR-TB is a major health challenge in Central Africa. Researchers are studying the molecular epidemiology and genetic characteristics of MDR-TB strains to better understand how the disease spreads and evolves. This study focuses on mutations linked to resistance against important drugs like bedaquiline and quinolones, which could affect new treatment regimens involving Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin. The research also examines the role of TB lineage in infection outcomes and transmission patterns. This observational study involves screening GeneXpert positive TB patients aged 9 and older who can provide sputum samples. Participants already enrolled in a related tuberculosis epidemiology study may also be included without additional consent. The study collects and shares data on the genetic makeup of TB strains, focusing on identifying resistance mutations and transmission links within and between countries. Participants provide sputum samples for laboratory analysis to characterize drug resistance mutations and detect transmission chains. The primary outcomes measured over six months include the proportion of drug-resistant strains with known resistance mutations, the proportion with new mutations among unexplained resistance cases, and the proportion of cases showing transmission connections. The study aims to improve understanding of MDR-TB spread and resistance in the region, with participation lasting up to the study completion date in December 2026.

Age: 9Years +All Genders
8 locations
P

Actively Recruiting

Researchers are investigating new treatment options for adults with newly diagnosed, drug-sensitive pulmonary tuberculosis through a phase 2BC open-label platform study. The trial compares several experimental drug regimens with a standard control treatment to assess efficacy and safety. Participants include adults aged 18 to 65 years with confirmed pulmonary tuberculosis sensitive to rifampicin and isoniazid. The study aims to optimize doses of existing drugs and introduce new medications to improve treatment outcomes. The study is divided into three stages. In stage 1, participants are randomly assigned to the control or one of two experimental arms containing high-dose rifampicin and other drugs for 12 to 17 weeks. Stage 2 adds an experimental arm including the drug BTZ-043, with participants allocated across four arms in varying ratios. Stage 3 begins after stages 1 and 2 complete enrollment, comparing the control arm with two new experimental arms involving novel drug combinations. Treatments are given once daily, with dosages adjusted by arm and weight. Participants will undergo sputum testing, chest X-rays, and molecular tests to confirm tuberculosis and drug sensitivity before enrollment. During the study, researchers will monitor participants through regular clinical assessments, laboratory tests, and electrocardiograms to track treatment response and safety. The main outcomes measured include time to stable culture conversion and changes in mycobacterial load. Safety is evaluated by recording adverse events and laboratory abnormalities over the treatment period, with follow-up continuing up to 12 months after randomization.

Age: 18Years - 65YearsAll GendersPhase 2
10 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination of anti-malarial drugs in children aged 2 to under 12 years with uncomplicated Plasmodium falciparum malaria. This phase 2 platform study compares a single oral dose of up to three anti-malarial agents given together to the standard treatment known as Coartem. The study aims to better understand how these treatments work and their safety profiles in this young population. Participants are randomly assigned to one of two groups one receiving an oral combination of KLU156 with KAE609 alongside a light meal, and the other receiving the standard of care, Artemether plus lumefantrine, given orally according to the usual guidelines. This open-label, two-arm study monitors each treatment groups response to therapy. Throughout the study, participants undergo evaluations including parasite clearance times and blood tests to measure drug levels over the first week, with the main outcome assessed on day 29 using PCR to confirm clinical and parasitological response. Safety and tolerability are also closely monitored, and the total duration of participation extends up to 29 days after treatment initiation to assess treatment outcomes comprehensively.

Age: 2Years - 12YearsAll GendersPhase 2
13 locations
S

Actively Recruiting

Researchers are evaluating how well different anti-malarial drugs work and how safe they are for treating uncomplicated Plasmodium falciparum malaria in adults, adolescents, and children. This study focuses on the parasite-killing effects and potential cure rates of these drugs when given alone or combined with others. It also looks at how the drugs are processed by the body to help decide doses for future studies. Participants will receive one of several treatments, including varying doses of the oral drug INE963, combinations of oral KAE609 Cipargamin with INE963 or KLU156, or the standard of care drug Coartem. The study has multiple parts with patients allocated randomly to different treatment groups. Dosing levels and combinations are tested to compare how effectively they clear the malaria parasite. During the study, participants will have their parasite levels monitored up to 7 days and clinical response assessed by day 29. Blood samples will be taken by day 22 to study drug levels and how the body absorbs and clears the medicines. Safety is monitored through reports of side effects until day 43. The total participation lasts through these assessments to understand treatment impact and tolerability.

Age: 2Years - 100YearsAll GendersPhase 2
12 locations